![Mikkel Dührkop](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mikkel Dührkop
Profile
Mikkel Dührkop joined Zymenex A/S in 2001.
He is Chief Operating Officer of Zymenex A/S.
Former positions of Mikkel Dührkop
Companies | Position | End |
---|---|---|
AGC Biologics A/S
![]() AGC Biologics A/S Pharmaceuticals: MajorHealth Technology AGC Biologics A/S provides contract process development and biopharmaceuticals manufacturing services worldwide. It specializes in delivering custom solutions for the scale-up and the cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials, and commercial production. Its services include cell line development, bioprocess development, formulation, and analytical testing. The company was founded by Peter Vilby, Mads Laustsen, Thomas Sandal, and Morten Munk in 2001 and is headquartered in Soeborg, Denmark. | Corporate Officer/Principal | - |
Zymenex A/S
![]() Zymenex A/S BiotechnologyHealth Technology Zymenex A/S researches and develops therapeutics for life threatening diseases. The firm commercializes novel enzyme replacement therapies for the treatment of life-threatening, rare genetic diseases. The company was founded by Jens Fogh and Pär Gellerfors in 1998 and is headquartered in Hillerod, Denmark. | Chief Operating Officer | - |
Training of Mikkel Dührkop
University of Copenhagen | Graduate Degree |
Experiences
Positions held
Linked companies
Private companies | 2 |
---|---|
Zymenex A/S
![]() Zymenex A/S BiotechnologyHealth Technology Zymenex A/S researches and develops therapeutics for life threatening diseases. The firm commercializes novel enzyme replacement therapies for the treatment of life-threatening, rare genetic diseases. The company was founded by Jens Fogh and Pär Gellerfors in 1998 and is headquartered in Hillerod, Denmark. | Health Technology |
AGC Biologics A/S
![]() AGC Biologics A/S Pharmaceuticals: MajorHealth Technology AGC Biologics A/S provides contract process development and biopharmaceuticals manufacturing services worldwide. It specializes in delivering custom solutions for the scale-up and the cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials, and commercial production. Its services include cell line development, bioprocess development, formulation, and analytical testing. The company was founded by Peter Vilby, Mads Laustsen, Thomas Sandal, and Morten Munk in 2001 and is headquartered in Soeborg, Denmark. | Health Technology |
- Stock Market
- Insiders
- Mikkel Dührkop